ANGLE plc (GB:AGL) has released an update.
ANGLE plc has unveiled promising new data at the AACR Special Conference, highlighting the development of a Parsortix-based HER2 assay kit for metastatic breast cancer patients. This innovative solution allows for the continuous assessment of HER2 status, potentially identifying patients who could benefit from targeted therapies. The study revealed significant cases where HER2 status changed over time, underscoring the potential of this assay in personalized cancer treatment.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
